| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 156.41 | 7.5% |
| Total Income | 156.41 | 7.5% |
| Expenditure | 858.01 | 590.2% |
| PBT | -720.81 | 94943.4% |
| Net Profit | -721.81 | 2406133.3% |
| OPM | — | |
| NPM | — | |
| EPS | -2.98 |
BioCryst Reports Q1 2026: ORLADEYO Revenue $148.3M, Up 11% Y-o-Y
06 May 2026 · 6 May, 4:42 pm
Summary
BioCryst Pharmaceuticals reported its financial results for the first quarter ended March 31, 2026. ORLADEYO net revenue reached $148.3 million, representing an 11% year-over-year increase. The company also announced a licensing agreement for navenibart in Europe, receiving $70 million upfront. Patient enrollment in the navenibart ALPHA-ORBIT study is progressing as planned, with regulatory filing expected by the end of 2027. The company maintains its full year 2026 revenue guidance for ORLADEYO between $625 million and $645 million.
Key Highlights
- 1
BioCryst reported Q1 2026 ORLADEYO net revenue of $148.3 million, an increase of 11% year-over-year.
- 2
Excluding European revenue, ORLADEYO revenue grew by 21% year-over-year on a comparable basis.
- 3
The company announced a licensing agreement for European commercial rights to navenibart, receiving $70 million upfront and potential milestone payments up to $275 million.
- 4
Patient enrollment in the ALPHA-ORBIT study of navenibart is on track to be completed by the end of June 2026, supporting a regulatory filing in the US by the end of 2027.
- 5
BioCryst is studying BCX17725 for Netherton syndrome in a Phase 1 trial, with data expected by the end of 2026.
- 6
The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million.
- 7
The company recorded a GAAP operating loss of $701.6 million for Q1 2026, primarily due to a special, non-cash charge related to acquired in-process research and development.
Management Comments
Charlie Gayer
“We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline. ORLADEYO continues to grow because its differentiated oral profile and high level of attack control meet the needs of an increasing number of people living with hereditary angioedema. At the same time, we remain on track with enrollment in our navenibart and BCX17725 pipeline programs. We are also pleased to partner again with Neopharmed Gentili for European rights to navenibart. This progress underscores our strategy to focus on rare diseases where we have deep expertise, execute efficiently, and allocate capital thoughtfully to drive sustainable value for patients and shareholders.”
Informational and educational content only. Not investment advice.